: Beverly A. Teicher, Lee M. Ellis
: Antiangiogenic Agents in Cancer Therapy
: Humana Press
: 9781597451840
: 2
: CHF 190.40
:
: Nichtklinische Fächer
: English
: 559
: Wasserzeichen/DRM
: PC/MAC/eReader/Tablet
: PDF

This volume represents a compendium of scientific findings and approaches to the study of angiogenesis in cancer. The second edition of Antiangiogenic Agents in Cancer Therapy is intended to give a current perspective on the state-of-the-art of angiogenensis and therapy directed at this process.

Antiangiogenes s is a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge.
Preface6
Contents7
Contributors10
I Basic Biology of Angiogenesis18
Vascular Endothelial Growth Factor Family and Its Receptors19
The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors43
The Role of Integrins in Tumor Angiogenesis64
Tumor Endothelial Cell Abnormalities87
The Extracellular Matrix and VEGF Processing99
Endothelial Precursor Cells112
Role of Pericytes in Angiogenesis129
Newer Vascular Targets145
Chemokines in Angiogenesis166
Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis182
Imaging Angiogenesis199
Tumor Blood Vessels214
Lymphatic System in the Pathology of Cancer234
II Translational Research in Tumor Angiogenesis251
VEGF in the Adult252
Normalization of Tumor Vasculature and Microenvironment267
Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man283
Small-Molecule Vascular Disrupting Agents in Cancer Therapy303
Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents317
Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside328
Regulation of Angiogenesis in Cancer and Its Therapeutic Implications336
III Antiangiogenic Therapy in the Clinical Trial Results and Future Directions355
Angiogenesis and Angiogenesis Inhibition in Sarcomas356
Antiangiogenesis Agents in Colorectal Cancer373
Antiangiogenic Therapy for Primary CNS Tumors413
Angiogenesis Inhibitors for the Treatment of Lung Cancer437
Antiangiogenic Therapy of Renal Cell Carcinoma455
Antiangiogenesis Therapies in Gynecologic Malignancies468
Antiangiogenic Agents in Myeloid Malignancies484
Angiogenesis in Malignant and Non- Malignant Pediatric Tumors501
Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis513
Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials535
The Role of Imaging in the Clinical Development of Antiangiogenic Agents551
Index563